Parkinsons disease is the most common neurodegenerative movement disorder. Over the past few years, studies have identified a number of genes that cause or contribute to the pathogenesis of this disorder. Pathophysiologically, Parkinsons disease is characterized by a progressive loss of dopaminergic nigrostriatal neurons, a process that to this date cannot be effectively stopped or slowed down by any available pharmacological treatment. A systematic analysis of genes and genetic networks involved in this neurodegenerative process is uncovering new molecular pathways with the hope of identifying potential new pharmacological targets for a disease-modifying treatment of Parkinsons disease. The goal of this presentation is to highlight some of these genes and pathways